Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin
Taken together, the figure highlights a key mechanistic principle underlying the therapeutic rationale for multi-agonist strategies: while GLP-1R monotherapy achieves meaningful metabolic and hepatic benefits exclusively through indirect, systemic pathways, the addition of GIPR and - most importantly - GCGR co-agonism introduces complementary and increasingly direct hepatic mechanisms, providing the pharmacological basis for the superior efficacy observed with dual and triple agonists in MASLD/MASH
3.6.1 Defining ROPE and clinical significance While frequentist meta-analyses are widely applied within the PCOS evidence-based framework, their conclusions often fail to directly address threshold-based clinical questions
Supplements may include a mulvitamin/mineral supplement, supplements for muscle support and certain probiotics
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
FIGURE 3 8.4 Health economics and access: important implementation questions, but no PCOS-ART-specific economic evidence yet A structural tension exists between the clinical promise and the cost of GLP-1RAs
